For those who don't go back that far, Jeff Craws/Crystal Research first started covering Unilife in 2009. He's a highly respected, multi-award winning biotech/pharma analyst. He understands the company and the industry we're in as well as anyone, often better. Good to see he's still on board. Has skin in the game, too. Says a lot.
As for me, well, taking advantage of recent weakness to pick up a few more, as resources allow. Whoever has been responsible, thanks.
IMO we are approaching end-game time. Not in a negative way. There are multiple signals indicating that the delay in the BIG ONE is just that. Nothing sinister. Just a fact of life in this business.
When it breaks, there are going to be more than a few people wishing they had seen things with the precision of hindsight, unclouded by emotion, as much of the commentary here has been of late.
Good luck, anyway. We're not going to need it.
As always, IMVHO.
UNS Price at posting:
50.5¢ Sentiment: Buy Disclosure: Held
